Asian Stocks Rise as Korea Tech Shares Rebound 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Peru Economy Grows 2.6% in Q2 as Private Investment Surges 
Japan Inflation Rises, Boosting BOJ Rate Hike Bets 
US Plans ‘Toughest Sanctions in History’ on Iran, Bessent Says 
Gold Holds Above $4,500 as Dollar Weakens 
SK Hynix Shares Surge on Record $28.6 Billion Buyback 
UK Budget Swings to Surprise £1.8 Billion Deficit in July 
Samsung Eyes $72 Billion Shareholder Return Plan as AI Chip Boom Fuels Profits 
Barclays Downgrades Renault as Cost Savings Challenges Grow 
SpaceX Hires Natural Gas Trader to Meet Growing Energy Needs 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
CK Hutchison Seeks $1.5 Billion From Panama Over Canal Ports 
Dollar Hovers Near Multi-Month Lows as Treasury Buybacks Rattle Markets 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Alibaba Shares Fall as AI Spending Hits Profit 
Gold Prices Hit Three-Month High as Dollar Weakens 
Add as a preferred source on Google
Eli Lilly gets a subpoena from the U.S. Department of Justice with regards to its manufacturing factory in New Jersey that produces COVID-19 treatment called bamlanivimab. Based on the report, the DOJ wants the pharmaceutical company to forward some documents.
As per Reuters, while it was not specified what documents are being requested by the officials, they are something related to Eli Lilly’s factory site in Branchburg, New Jersey. The company said that it is actively participating and fully cooperating with the investigation.
The issue with Eli Lilly’s NJ plant
Earlier this month, some of Eli Lilly’s employees alleged that an executive in the NJ plant altered the documents so it can pass quality control without a problem. The papers are required by regulators for the operation of the company’s factory, but with the modification, the employees feared it would cause serious quality control issues.
It was relayed that in November 2019, inspectors from the U.S. Food and Drug Administration were sent over to check Eli Lilly’s Branchburg factory. They discovered that much of the data related to manufacturing processes were deleted while others were not inappropriately audited.
The pharmaceutical company is also said to be facing issues with its quality control and production at its plant in Indianapolis. This is the site where bamlanivimab and other medicines are being bottled.
Lilly conducting its own internal probe
As per Financial Post, Eli Lilly also launched its own investigation concerning the allegations. The company also hired counsel who will carry out an independent probe in its New Jersey facility.
“Lilly is deeply committed to manufacturing high-quality medicines for patients who need them, and the safety and quality of our products is our highest priority,” the firm stated.
In any case, while the investigation is ongoing, Eli Lilly published the subpoena issued to them by the DOJ. This move shows that the company is being transparent with the investigation and doing its best to resolve the problems too. Meanwhile, the company could not comment further on the case as of this time since a conclusion has not been reached yet.
